Resolution of severe macular edema in adult coats' disease with intravitreal triamcinolone and bevacizumab injection.
A 47 year old male patient visited our hospital with the chief complaint of deterioration of the visual acuity in the left eye. The fundus examination revealed thick hard exudates, multiple aneurysms and telangiectasias of the retinal vessels in the posterior pole. Fluorescein angiography demonstrated massive leakage over an area of the aneurysms. Optical coherence tomography (Stratus OCT; Zeiss-Humphrey, Dubin, CA) revealed diffuse and marked thickening of the retina. Laser photocoagulation was performed under the diagnosis of Coats' disease. However, the treatment could not be performed satisfactorily. On the first and 6th weeks, an intravitreal injection of bevacizumab and triamcinolone acetonide was administered, and laser photocoagulation was again attempted. The effectiveness of eachagent on retinal edema was evaluated at the follow-up performed at 1, 2, 5, 7, 10 weeks and 6 months after the injection. At one week after the intravitreal bevacizumab injection, there was no improvement. An intravitreal injection of triamcinolone acetonide was performed 6 weeks after the initial diagnosis,which resulted in a reduction in the thickness of the macular edema. Therefore, laser photocoagulation was performed sufficiently on telangiectasias. The follow-up at 6 months showed a relative increase in the macular edema, but there was reduced leakage from the telangiectasias compared with the previous angiograph.
Jun
Jong Hwa
JH
Department of Ophthalmology, School of Medicine, Dongsan Medical Center, Keimyung University, Daegu, Korea.
Kim
Yu Cheol
YC
Kim
Kwang Soo
KS
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004359:Drug Therapy, Combination; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D017075:Laser Coagulation; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D012164:Retinal Diseases / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D012171:Retinal Vessels / Q000473:pathology; D013684:Telangiectasis / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D041623:Tomography, Optical Coherence; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide
Br J Ophthalmol. 2007 Mar;91(3):303-6
17020897
Br J Ophthalmol. 2004 Apr;88(4):587-8
15031187
Retina. 2002 Feb;22(1):80-91
11884883
Br J Ophthalmol. 1971 May;55(5):289-301
4102954
Am J Ophthalmol. 2001 May;131(5):572-83
11336931
Semin Ophthalmol. 2004 Sep-Dec;19(3-4):117-8
15590551
Eye (Lond). 2006 Feb;20(2):163-5
15723038
Am J Ophthalmol. 2001 May;131(5):561-71
11336930
Int Ophthalmol Clin. 2001 Fall;41(4):189-98
11698747
J Pediatr Ophthalmol Strabismus. 2005 Nov-Dec;42(6):367-8
16382562
Graefes Arch Clin Exp Ophthalmol. 2007 Sep;245(9):1387-8
17342503
Ophthalmology. 2005 Jun;112(6):1072-8
15882905